Company Filing History:
Years Active: 2010-2012
Title: Dirk Chelius: Innovator in Polypeptide Formulations
Introduction
Dirk Chelius is a notable inventor based in Geretsried, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of stable polypeptide formulations. With a total of 2 patents to his name, Chelius continues to push the boundaries of innovation in therapeutic applications.
Latest Patents
One of Dirk Chelius's latest patents focuses on stable polypeptide formulations. This invention provides a formulation that includes a buffer with a pH less than 6.0, a divalent cation concentration ranging from about 5-200 mM, and an excipient comprising a sugar or polyol. Additionally, it outlines a method for stabilizing a polypeptide by contacting it with a divalent cation concentration between about 5-150 mM in a buffer with a pH less than 6.0, along with an excipient comprising a sugar or polyol.
Career Highlights
Dirk Chelius is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to focus on innovative solutions in the field of therapeutic polypeptides. His expertise and dedication have contributed to advancements in drug formulation and stability.
Collaborations
Throughout his career, Dirk has collaborated with esteemed colleagues such as Douglas Rehder and Pavel V Bondarenko. These collaborations have fostered a productive environment for innovation and research in the biopharmaceutical sector.
Conclusion
Dirk Chelius stands out as a prominent inventor in the realm of polypeptide formulations. His contributions to the field are marked by his innovative patents and collaborations, which continue to influence therapeutic advancements.